BioLife Solutions Inc. (BULLETIN BOARD: BLFS) , a leading developer and manufacturer of proprietary preservation media for cells, tissues, and organs, today announced the appointment of Andrew G. Hinson as a director to fill the vacancy on its board of directors created by the resignation of John G. Baust.

Hinson, 41, a resident of Washington, D.C., is vice president of clinical and regulatory affairs for Symphony Medical, Inc., a privately held developer of proprietary biopolymer and cellular-based biologic therapies to treat arrhythmias, structural heart disease, and other cardiac abnormalities. Prior to joining Symphony Medical in November 2004, he was senior director of clinical development at AnGes Inc, a biotechnology firm developing novel gene-based approaches for the treatment of cardiovascular disease. During his stay at AnGes from 2002 to 2004, Hinson guided AnGes' successful filings of investigational new drug (IND) applications in the U.S. and Japan and advanced combinations of device and biologics into early and late stage clinical programs.

Prior to AnGes, Hinson was senior manager of medical and scientific affairs at Procter & Gamble Pharmaceutical (P&GP). During his tenure from 1993 to 2002 at P&GP, his responsibilities also included research and clinical development in a variety of areas including arrhythmia, heart failure, hypertension and myocardial injury. Hinson also has extensive experience with cell and gene therapies and extensive experience managing clinical trials for new biologic-based therapies.

BioLife Chief Executive Mike Rice commented: "We're very pleased that Andy has joined our board of directors. He brings a wealth of experience directly relevant to our new focus on the high-growth cellular therapy market. He will not only help advance the Company's intellectual-property development but also guide our collaborations with academia and industry to gain additional insight into our target markets and customers."

About BioLife Solutions

BioLife Solutions develops, manufactures and markets patented hypothermic storage and cryopreservation solutions for cells, tissues, and organs. The Company's proprietary HypoThermosol® and CryoStor™ preservation media are marketed to companies, laboratories, and academic institutions engaged in research and commercial clinical applications. BioLife's line of serum-free and protein-free preservation solutions are fully defined and formulated to reduce or prevent preservation-induced, delayed-onset cell damage and death. BioLife's platform enabling technology provides academic and clinical researchers significant improvement in post-thaw cell, tissue, and organ viability and function.

For more information please visit BioLife Solutions' website at www.biolifesolutions.com.

This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

  Media Relations Contact:          Investor Relations Contacts:
  Len Hall                          Matt Clawson or Dan Matsui
  Allen & Caron, Inc.               Allen & Caron, Inc.
  (949) 474-4300                    (949) 474-4300
  len@allencaron.com                matt@allencaron.com

SOURCE: BioLife Solutions Inc.